Literature DB >> 20817880

IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.

Meghan E Turnis1, Xiao-Tong Song, Adham Bear, Aaron E Foster, Stephen Gottschalk, Malcolm K Brenner, Si-Yi Chen, Cliona M Rooney.   

Abstract

To function optimally as vaccines, dendritic cells (DCs) must actively migrate to lymphoid organs and maintain a viable, mature state for sufficient time to effectively present their Ag to cognate T cells. Unfortunately, mature DCs rapidly lose viability and function after injection, and only a minority leaves the vaccine site and migrates to lymph nodes. We show that all of these functions can be enhanced in DCs by removal of IL-1R-associated kinase M (IRAK-M). We found that IRAK-M is induced in DCs by TLR ligation and that its absence from these cells leads to increased activation of the p38-MAPK and NF-κB pathways, which, in turn, improves DC migration to lymph nodes, increases their longevity, and augments their secretion of Th1-skewing cytokines and chemokines. These biological effects have immunological consequences. IRAK-M(-/-) DCs increase the proliferation and activation of Ag-specific T cells, and a single vaccination with Ag-pulsed, LPS-matured IRAK-M(-/-) DCs eliminates established tumors and prolongs the survival of EG7 or B16.f10 tumor-bearing mice, without discernible induction of autoimmune disease. Thus, manipulation of IRAK-M levels can increase the potency of DC vaccines by enhancing their Ag-presenting function, migration, and longevity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20817880      PMCID: PMC3153346          DOI: 10.4049/jimmunol.0903507

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.

Authors:  I Jolanda M De Vries; Daniëlle J E B Krooshoop; Nicole M Scharenborg; W Joost Lesterhuis; J Heleen S Diepstra; Goos N P Van Muijen; Simon P Strijk; Theo J Ruers; Otto C Boerman; Wim J G Oyen; Gosse J Adema; Cornelis J A Punt; Carl G Figdor
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

2.  Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.

Authors:  Carsten Wiethe; Kurt Dittmar; Tracy Doan; Werner Lindenmaier; Robert Tindle
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

3.  Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells.

Authors:  Tanja Maier; Adrian Tun-Kyi; Anatoli Tassis; Karl-Peter Jungius; Günter Burg; Reinhard Dummer; Frank O Nestle
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

Review 4.  Some interfaces of dendritic cell biology.

Authors:  Ralph M Steinman
Journal:  APMIS       Date:  2003 Jul-Aug       Impact factor: 3.205

5.  Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.

Authors:  Volker L Reichardt; Caterina Milazzo; Wolfram Brugger; Hermann Einsele; Lothar Kanz; Peter Brossart
Journal:  Haematologica       Date:  2003-10       Impact factor: 9.941

Review 6.  Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies.

Authors:  Christine Daly; Barrett J Rollins
Journal:  Microcirculation       Date:  2003-06       Impact factor: 2.628

Review 7.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

Review 8.  The use of dendritic cells in cancer immunotherapy.

Authors:  Gerold Schuler; Beatrice Schuler-Thurner; Ralph M Steinman
Journal:  Curr Opin Immunol       Date:  2003-04       Impact factor: 7.486

9.  Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines.

Authors:  Adam S Giermasz; Julie A Urban; Yutaro Nakamura; Payal Watchmaker; Rachel L Cumberland; William Gooding; Pawel Kalinski
Journal:  Cancer Immunol Immunother       Date:  2009-01-21       Impact factor: 6.968

10.  Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming.

Authors:  Alfonso MartIn-Fontecha; Silvia Sebastiani; Uta E Höpken; Mariagrazia Uguccioni; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  17 in total

1.  DNA methylation screening identifies driver epigenetic events of cancer cell survival.

Authors:  Daniel D De Carvalho; Shikhar Sharma; Jueng Soo You; Sheng-Fang Su; Phillippa C Taberlay; Theresa K Kelly; Xiaojing Yang; Gangning Liang; Peter A Jones
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

Review 2.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

3.  Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells.

Authors:  M Jeyanathan; S McCormick; R Lai; S Afkhami; C R Shaler; C N Horvath; D Damjanovic; A Zganiacz; N Barra; A Ashkar; M Jordana; N Aoki; Z Xing
Journal:  Mucosal Immunol       Date:  2013-10-30       Impact factor: 7.313

4.  Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts.

Authors:  Wei Chen; Amit Saxena; Na Li; Jinyu Sun; Amit Gupta; Dong-Wook Lee; Qi Tian; Marcin Dobaczewski; Nikolaos G Frangogiannis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

5.  Critical Role of IRAK-M in Regulating Antigen-Induced Airway Inflammation.

Authors:  Mingqiang Zhang; Wei Chen; Weixun Zhou; Yan Bai; Jinming Gao
Journal:  Am J Respir Cell Mol Biol       Date:  2017-11       Impact factor: 6.914

6.  The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.

Authors:  Y-H Ahn; S-O Hong; J H Kim; K H Noh; K-H Song; Y-H Lee; J-H Jeon; D-W Kim; J H Seo; T W Kim
Journal:  Clin Exp Immunol       Date:  2015-05-17       Impact factor: 4.330

Review 7.  Cell Signaling Pathways That Regulate Antigen Presentation.

Authors:  Randy R Brutkiewicz
Journal:  J Immunol       Date:  2016-10-15       Impact factor: 5.422

8.  Identification of Biologically Active Pyrimido[5,4-b]indoles That Prolong NF-κB Activation without Intrinsic Activity.

Authors:  Michael Chan; Alast Ahmadi; Shiyin Yao; Fumi Sato-Kaneko; Karen Messer; Minya Pu; Brandon Nguyen; Tomoko Hayashi; Maripat Corr; Dennis A Carson; Howard B Cottam; Nikunj M Shukla
Journal:  ACS Comb Sci       Date:  2017-07-13       Impact factor: 3.784

9.  IRAK-M Associates with Susceptibility to Adult-Onset Asthma and Promotes Chronic Airway Inflammation.

Authors:  Yi Liu; Mingqiang Zhang; Lili Lou; Lun Li; Youming Zhang; Wei Chen; Weixun Zhou; Yan Bai; Jinming Gao
Journal:  J Immunol       Date:  2019-01-07       Impact factor: 5.422

10.  An effective vaccination approach augments anti-HIV systemic and vaginal immunity in mice with decreased HIV-1 susceptible α4β7high CD4+ T cells.

Authors:  Wei Zhu; Guoping Shi; Haijun Tang; Dorothy E Lewis; Xiao-Tong Song
Journal:  Curr HIV Res       Date:  2013-01       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.